Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Profit After Tax (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Profit After Tax for 6 consecutive years, with -$16.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 47.97% year-over-year to -$16.9 million, compared with a TTM value of $13.3 million through Dec 2025, up 138.92%, and an annual FY2025 reading of $13.3 million, up 138.92% over the prior year.
  • Profit After Tax was -$16.9 million for Q4 2025 at SAB Biotherapeutics, down from $45.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $45.4 million in Q3 2025 and bottomed at -$22.9 million in Q4 2023.
  • Average Profit After Tax over 5 years is -$4.9 million, with a median of -$7.0 million recorded in 2022.
  • The sharpest move saw Profit After Tax tumbled 128307.03% in 2021, then soared 539.11% in 2025.
  • Year by year, Profit After Tax stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then crashed by 190.26% to -$22.9 million in 2023, then surged by 50.15% to -$11.4 million in 2024, then plummeted by 47.97% to -$16.9 million in 2025.
  • Business Quant data shows Profit After Tax for SABS at -$16.9 million in Q4 2025, $45.4 million in Q3 2025, and -$10.1 million in Q2 2025.